Arrythmia, Cardiometabolic Syndrome, Cardiomyopathies, Cardiovascular Diseases, Cerebrovascular Accident, Congenital Heart Disease, Heart Failure
Conditions
Brief summary
The Investigators will create a clinical database and a Biobank of stem cells derived from the blood of participants with cardiovascular disease. The Investigators will recruit participants from diverse racial and ethnic backgrounds with equal representation from both sexes. The Investigators expect to create stem cells and analyze the blood for protein biomarkers and genetic causes of cardiovascular disease. The stem cell biobank and clinical data will be a powerful tool for studying cardiovascular disease.
Detailed description
Cardiovascular disease is the leading cause of morbidity and mortality. The development of cardiovascular disease includes both genetic and epigenetic factors. Understanding their molecular and cellular mechanism is necessary to identify novel drug targets and treat the disease. Present in vitro and in vivo models of the disease do not mimic human pathophysiology, and obtaining the primary cells from the patients for the studies relevant to the cardiovascular and pulmonary system is difficult. Induced pluripotent stem cells (iPSCs) are derived from a person's blood cells and facilitate the discovery of cardiovascular disease mechanisms. The Investigators propose recruiting cardiovascular patients from diverse ethnic backgrounds and creating a rich clinical database using REDCap. Blood samples will be obtained from participants and used to create iPSCs. The participant will have DNA sequencing, and serum will be analyzed for protein biomarkers. The multi-omics data and reprogrammed iPSCs will be stored in the Cardiology and Critical Care (C3RP) laboratory at the Robarts Research Institute at Western University. The reprogrammed iPSCs can generate a limitless supply of cardiovascular tissue. Moreover, the iPSC-derived data will be correlated with clinical information, genetic sequencing, and protein biomarkers from serum analysis. The Investigators expect to create an iPSC biobank coupled with a rich clinical dataset, including genetic sequencing analysis and protein biomarkers that will enable the discovery of novel biomarkers and drug targets for cardiovascular disease.
Interventions
None listed
Sponsors
Greenstone Biosciences, Inc.
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Adult (18 to 80 years of age) * Cardiovascular Disease (CVD) * Cerebrovascular Disease (CBD) * Peripheral Vascular Disease (PVD) * Inherited Arrhythmias * Cardiomyopathies * Congenital Heart Disease (CHD) * Aortopathy * Hypertension * Cardiometabolic Disease (CMD)
Exclusion criteria
* Younger than 18 years of age. * Patients not able to provide consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| REDCap Database | 10 years | Identify patients with cardiovascular disease from ethnically diverse backgrounds and create a clinical database with REDCap. |
| Induced pluripotent stem cell (iPSC) Biobank | 10 years | Reprogram peripheral blood mononuclear cells (PBMC) to iPSCs. |
| Differentiation into Cardiovascular lineages | 10 years | Differentiate of iPSCs into different cardiovascular lineages (endothelial cells, smooth muscle cells, cardiomyocytes, etc.) |
| Molecular profiling of participants | 10 years | Molecular profiling of iPSC-derived tissue and patient serum using microarray, DNA sequencing, and high throughput omics technologies (transcriptomic analysis, proteomic analysis, metabolomic studies, and functional assays). |
| Bioinformatics analysis | 10 years | Bioinformatics analysis of clinical, iPSC disease modeling, and serum omics analysis. |
Countries
Canada
Outcome results
None listed